The Investment Column: SkyePharma
Friday 03 September 1999
The attraction of the group, which aims to be a specialist in drug delivery mechanisms, is the promise of riding on the back of the earnings streams of major pharmaceuticals groups employing its services. The star is Paxil CR, a variation of a SmithKline Beecham drug. But the treatment has not yet gone to market because SmithKline's existing Paxil drug has retained patent protection.
No wonder SkyePharma is broadening its portfolio. It has gained two new products this year with the acquisition in March of California-based DepoTech. DepoCyte, a meningitis treatment in which it has a 50 per cent stake of royalties, hit the market in May; its sales - pounds 1.3m in the period - are meeting expectations, but it will not be a blockbuster. DepoMorphine, a painkiller for hip surgery, has a potentially larger market but is still in trials.
The half-year sales hike followed rises in research and development income and royalties. After a pounds 2m hit from the cost of listing in the US, underlying losses narrowed from pounds 7.5m to pounds 3.8m in the first half. Analysts expect a full-year loss of pounds 11m, with maiden profits in the first half next year.
With the group lacking a deal to provide guaranteed and substantial revenues, the shares are risky.
- 1 Cyclist who knocked down three-year-old girl says his life has been 'destroyed'
- 2 Chelsea victory parade: Chelsea mocked on Twitter as 'tens of fans' pack the streets of London
- 3 US warned by Chinese media to stop meddling or 'war will be inevitable'
- 4 Woman, 21, dies after taking contraceptive pill that 'caused fatal blood clot'
- 5 Isis burns woman alive for refusing to engage in 'extreme' sex act, UN says
Cyclist who knocked down three-year-old girl says his life has been 'destroyed'
US warned by Chinese media to stop meddling or 'war will be inevitable'
How China's richest man Li Hejun lost $15bn in an hour - and made a fortune
Isis burns woman alive for refusing to engage in 'extreme' sex act, UN says
Snoop Dogg on why he doesn't regret displaying misogyny towards women
As a white man, I'm surprised more women aren't tweeting the hashtag #KillAllWhiteMen
Scotland may have to leave the EU even if it votes to stay in, David Cameron confirms
The day that Britain resigned as a global power
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
A nation of inequality: How the UK is failing to feed its most vulnerable people
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
iJobs Money & Business
£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...
£45,000 - £55,000: Neil Pavier: Are you looking for your next opportunity for ...
£45,000 - £55,000: Sheridan Maine: Are you a newly qualified ACA/ACCA/ACMA qua...
£50,000 - £60,000: Laura Norton: Are you looking for an opportunity within a w...